Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 3 to 4 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.44 [0.1, 1.95] | 1 study · 969 participants | Very low |
Casirivimab/imdevimab vs placebo Adverse events: all grades within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 1.14 [0.98, 1.31] | 1 study · 969 participants | Low |
Casirivimab/imdevimab vs placebo Serious adverse events within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.82 [0.16, 4.21] | 1 study · 969 participants | Very low |
Bamlanivimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.18 [0.09, 0.35] | 1 study · 5172 participants | High |
Bamlanivimab vs placebo Infection with SARS‐CoV‐2 by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.76 [0.59, 0.98] | 1 study · 966 participants | Moderate |
Bamlanivimab vs placebo Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.83 [0.25, 2.7] | 1 study · 966 participants | Low |
Bamlanivimab vs placebo Admission to hospital within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 3 to 4 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: all grade by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 1.12 [0.86, 1.46] | 1 study · 966 participants | Low |
Bamlanivimab vs placebo Serious adverse events by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 1.46 [0.73, 2.91] | 1 study · 966 participants | Low |
Casirivimab/imdevimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo All‐cause mortality within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.64 [0.24, 1.73] | 1 study · 5197 participants | Low |
Casirivimab/imdevimab vs placebo Infection with SARS‐CoV‐2 by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.34 [0.23, 0.48] | 1 study · 1505 participants | High |
Casirivimab/imdevimab vs placebo Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.19 [0.1, 0.35] | 1 study · 1505 participants | High |
Casirivimab/imdevimab vs placebo All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 3 [0.12, 73.43] | 1 study · 1505 participants | Low |
Casirivimab/imdevimab vs placebo Admission to hospital by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.11 [0.01, 2.06] | 1 study · 1505 participants | Low |
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 3 to 4 until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.5 [0.24, 1.02] | 1 study · 2617 participants | Low |
Casirivimab/imdevimab vs placebo Adverse events: all grade until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.7 [0.61, 0.8] | 1 study · 2617 participants | High |
Casirivimab/imdevimab vs placebo Serious adverse events until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.66 [0.3, 1.47] | 1 study · 2617 participants | Low |
Tixagevimab/cilgavimab vs placebo Admission to hospital within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 0.03 [0, 0.59] | 1 study · 5197 participants | Low |
Tixagevimab/cilgavimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 3 to 4 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: all grade within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 1 [0.94, 1.07] | 1 study · 5197 participants | Low |
Tixagevimab/cilgavimab vs placebo Serious adverse events within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | RR 1.12 [0.83, 1.52] | 1 study · 5197 participants | Low |
Summary of findings table ‐ Corticosteroids plus standard care vs standard care (plus/minus placebo) All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | RR 0.9 [0.84, 0.97] | 9 studies · 7898 participants | Moderate |
Summary of findings table ‐ Methylprednisolone vs dexamethasone All‐cause mortality up to 120 days ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Invasive fungal infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | RR 0.87 [0.73, 1.04] | 3 studies · 1269 participants | Low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | RR 0.93 [0.79, 1.08] | 4 studies · 1383 participants | Very low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | RR 0.98 [0.89, 1.09] | 1 study · 200 participants | Low |
Summary of findings table ‐ Corticosteroids plus standard care vs standard care (plus/minus placebo) All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | RR 0.74 [0.23, 2.34] | 3 studies · 485 participants | Very low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | 2 studies · 1080 participants | Very low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Adverse events (any grade) ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | 1 study · 98 participants | Very low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | 2 studies · 1080 participants | Very low |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Invasive fungal infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | 2 studies · 1080 participants | Very low |